Sun Pharma delivered an 11.8% year-on-year rise in consolidated revenue to Rs 16,100 crore, supported by a 17.3% surge in Indian formulation sales. However, adjusted net profit declined to Rs 3,162 crore as litigation expenses compressed operating margins to 29.3%. In addition, United States sales decreased 8.2% to $455 million, partly offset by gains across emerging and international markets. During the period, research and development spending stood at Rs 778 crore, representing 4.8% of total sales.
Key points
Strong domestic performance helped drive total top-line growth despite persistent headwin…: Strong domestic performance helped drive total top-line growth despite persistent headwinds in the American market.
Elevated litigation charges materially hindered the pharmaceutical company's quarterly pr…: Elevated litigation charges materially hindered the pharmaceutical company's quarterly profitability and EBITDA margin profile.
Regulatory approvals for specialty products and clearances for the Organon acquisition ke…: Regulatory approvals for specialty products and clearances for the Organon acquisition keep long-term expansion goals on schedule.
Sources checked by our analysis pipeline: 1
India’s largest drug maker reported an 11.8% year-on-year increase in consolidated revenue to Rs 16,100 crore for the second quarter driven by growth in India and emerging markets. Adjusted net profit was Rs 3,162 crore.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 4.8% to Rs 4,744 crore, with the operating margin contracting to 29.3% from 31.3% a year earlier.
“Our performance during the quarter was driven by strong momentum in India, emerging markets and rest of world,” said managing director Kirti Ganorkar.
India formulations was a key growth driver, with sales rising 17.3% to Rs 5,552 crore. The domestic business accounted for 34.5% of consolidated sales during the quarter.
The company’s performance in emerging markets was also strong, with formulation sales increasing 7.6% to $350 million. Sales in other international markets grew 3.1% to $241 million.
However, US formulation sales declined 8.2% to $455 million, accounting for around 27% of consolidated revenue. The US business remains a key market for the company’s generics portfolio, alongside its expanding innovative medicines business.
On the GLP1 market, Dilip Shanghvi, executive chairman,…
The enterprise software giant is expanding its reach into defense tech by absorbing a specialized startup focused on artificial intelligence logistics. Valued at $375 million, the transaction represents a notable pivot toward defense operations and national security applications. This maneuver positions the cloud company to service specialized public sector supply chain requirements.
Stronger financial positioning has propelled the tech firm ahead of its industry rivals in the competitive cloud market. Market analysts attribute this leadership to multiple underlying factors that reinforce its commercial durability. Consequently, the company has secured a dominant standing among financial analysts and top institutional investors.
The Madison-based utility is ramping up infrastructure investments to absorb historic consumption spikes driven by artificial intelligence and broader electrification across the Midwest. System peak demand is projected to surge over 60 percent by 2031, prompting management to raise multi-year capital expenditure plans to ensure grid reliability. These strategic expansions position the utility to benefit from sustained commercial load growth while strengthening its long-term financial guidance.